GLP-1 medications
Tirzepatide and Semaglutide are being used as emerging options for cravings, alcohol use, and other substance use concerns when clinically appropriate.
Weight loss medications for addiction?
We’re sure by now you may have heard conversations, seen news articles, and advertisements everywhere about the injectable drugs popularly used to treat diabetes and weight loss. We are aware that recent studies have shown that the medications associated with weight loss may be effective in curbing cravings for alcohol and other substances.
A new case series that was published on November 27, 2023, in The Journal of Clinical Psychiatry, gives evidence that these medications, may also be useful in the treatment of alcohol use disorder. This novel investigation delves into the medication’s effectiveness beyond its established roles in managing type 2 diabetes and obesity. Through a series of clinical cases, the study explores how Semaglutide, might offer promising avenues for combating alcohol cravings and addressing AUD. These positive outcomes show it to become another effective tool offering hope for individuals grappling with alcohol-related challenges.
Semaglutide (Ozempic/ Wegovy) is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 medications reduce the release of dopamine, making previously ‘rewarding’ behaviors, like drinking alcohol or eating high fat/sugar foods, far less enjoyable. There has been more evidence that it may also be useful in treating alcohol use disorder.
Tirzepatide (Mounjaro/Zepbound) is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Similar to Semaglutide, it has also shown promising effects in treating conditions such as alcohol use disorders, type 2 diabetes, and obesity, and more.
Semaglutide / Tirzepatide: Starting at $250 monthly (Medication cost varies by medication and dose)
